You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Tacrolimus Salvage in AntiTumor Necrosis Factor Antibody Treatment-Refractory Crohns Disease

Gerich, Mark E. MD*; Pardi, Darrell S. MD; Bruining, David H. MD; Kammer, Patricia P. CCRP; Becker, Brenda D.; Tremaine, William T. MD

Inflammatory Bowel Diseases:
doi: 10.1097/MIB.0b013e318280b154
Original Clinical Article

Background: Several small retrospective studies have reported encouraging response rates in patients with Crohn’s disease (CD) treated with tacrolimus.

Methods: We conducted a retrospective study of the use of oral tacrolimus for severe CD refractory to anti–tumor necrosis factor agents. Response was defined as a clinician’s assessment of improvement after at least 7 days of treatment of one or more of the following: bowel movement frequency, fistula output, rectal bleeding, abdominal pain, extraintestinal manifestations, or well-being. Remission required all of the following: <3 stools per day, no bleeding, abdominal pain or extraintestinal manifestations, and increased well-being.

Results: Twenty-four eligible patients were treated with tacrolimus for a median of 4 months. Approximately 37% were steroid dependent or steroid refractory. Response and steroid-free remission rates were 67% and 21%, respectively, and lasted for a median of 4 months. Approximately 42% of patients were able to stop steroids and 54% of patients ultimately required surgery within a median of 10 months after starting tacrolimus. Patients with mean tacrolimus trough levels of 10 to 15 ng/mL had the highest rates of response (86%) and remission (57%). Surgery seemed to be postponed in this group compared with others. An adverse event occurred in 75% of patients. Eight of these events (33%) required dose reduction and 6 (25%) led to treatment discontinuation. There were no irreversible side effects or deaths attributable to tacrolimus over a median follow-up of 56 months.

Conclusions: Oral tacrolimus seems to be safe and effective in some patients with severe CD refractory to anti–tumor necrosis factor therapy, particularly at a mean trough level of 10 to 15 ng/mL.

In Brief

Article first published online 20 March 2013

Author Information

*Division of Gastroenterology and Hepatology, University of Colorado Denver, Aurora, Colorado; and

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Reprints: Mark Gerich, MD, Division of Gastroenterology and Hepatology, University of Colorado Denver, 12631 East 17th Avenue, MS B158, Aurora, CO 80045 (e-mail:

The authors have no conflicts of interest to disclose.

Received August 15, 2012

Accepted August 22, 2012

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.